LifeWatch AG

EQS-Adhoc: LifeWatch AG: 2015 revenue growth of 9.8% in core US cardiac monitoring business


EQS Group-Ad-hoc: LifeWatch AG / Key word(s): Preliminary Results
LifeWatch AG: 2015 revenue growth of 9.8% in core US cardiac monitoring business

29.01.2016 / 19:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

--------------------------------------------------------------------------------
LifeWatch grew revenues in its core US cardiac monitoring business by 9.8% in
2015

Zug/Switzerland, January 29, 2016 - LifeWatch AG (SIX Swiss Exchange: LIFE), a
leading developer and provider of medical solutions and remote diagnostic
monitoring services to the digital health market, today announces preliminary
unaudited key figures for 2015.

LifeWatch increased revenues in its core US cardiac monitoring business by 9.8%
in 2015. Total revenue grew by 8.2%, which is slightly below guidance, as a
result of lower than expected device sales from the Far East and delays of FDA
regulatory clearances for its patch products, one of which received FDA
clearance earlier this month.

Based on preliminary unaudited numbers, LifeWatch expects an EBITDA margin,
after adjusting for one-off and unplanned events, of approximately 14%, which is
at the level indicated in its guidance. On an unadjusted basis, the EBITDA
margin is expected to be around 12%. Delays in the FDA clearance of our ACT
software for the Android operating system, which caused additional purchases of
more costly phones, as well as the refocusing of customer service activities in
the USA, resulted in additional costs leading to an expected adjusted EBIT
margin of between 6% and 7%, which is below guidance. On an unadjusted basis the
EBIT margin is expected to be between 4% and 5%. The establishment of our new
business in Turkey and the write-off of our remaining LifeWatch V inventory and
components resulted in a one-off cost of around USD 2 million.

Dr. Stephan Rietiker, CEO of LifeWatch, stated: "Despite unexpected delays in
obtaining FDA product clearances, 2015 was a very successful year for LifeWatch.
Revenue growth was significantly above the market and adjusted EBITDA of over
USD 14 million was the second best in the history of the company. We remain
positive for 2016, particularly given the recent FDA clearance and CE Mark for
our Mobile Cardiac Telemetry 1-Lead patch and expect double-digit revenue growth
and improving EBIT and EBITDA margins in 2016 and beyond."

LifeWatch will provide detailed information on its 2015 results on March 17,
2016.


For further questions:

LifeWatch AG
c/o Dynamics Group, Philippe Blangey / Doris Rudischhauser
Phone: +41 43 268 32 35 / +41 79 410 81 88
E-mail: investor-relations@lifewatch.com


About LifeWatch AG:
LifeWatch AG, headquartered in Zug and listed on SIX Swiss Exchange (LIFE),
Switzerland, is a leading healthcare technology and solution company,
specializing in advanced digital health systems and wireless remote diagnostic
patient monitoring services. LifeWatch's services provide physicians with
critical information to determine appropriate treatment and thereby improve
patient outcomes. LifeWatch AG has operative subsidiaries in the United States,
in Switzerland and in Israel, and is the parent company of LifeWatch Services
Inc., and LifeWatch Technologies, Ltd. LifeWatch Services, Inc. is a leading
U.S.-based provider of cardiac monitoring services and home sleep testing of
Obstructive Sleep Apnea (OSA). LifeWatch Technologies Ltd., based in Israel, is
a leading developer and manufacturer of telemedicine products. For additional
information, please visitwww.lifewatch.com.

Sign upfor customized e-mail alerts and documentation requests at
http://www.irlifewatch.com/alert-service.aspx

This press release includes forward-looking statements. All statements other
than statements of historical facts contained in this press release, including
statements regarding future results of operations and financial position, the
business strategy, and plans and objectives for future operations, are
forward-looking statements. The words "believe," "may," "will," "estimate,"
"continue," "anticipate," "intend," "expect" and similar expressions are
intended to identify forward-looking statements. LifeWatch AG has based these
forward-looking statements largely on current expectations and projections about
future events and financial trends that it believes may affect the financial
condition, results of operations, business strategy, short-term and long-term
business operations and objectives, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. In
light of these risks, uncertainties and assumptions, the forward-looking events
and circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. All forward-looking statements are based only on
data available to LifeWatch AG at the time of the issue of this press release.
LifeWatch AG does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND
SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A
GENERAL
CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN
OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE
UNITED STATES, OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF
LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER
THE UNITED STATES
SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED
STATES OR TO U.S. PERSONS ABSENT FROM REGISTRATION UNDER OR AN APPLICABLE
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES
LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE
MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG OR ITS
SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION ABOUT THE
ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE ISSUER.

End of ad hoc announcement

+++++
Additional features:

Document:http://n.eqs.com/c/fncls.ssp?u=AJJADHHYFG
Document title: LifeWatch grew revenues in its core US cardiac monitoring
business by 9.8% in 2015

--------------------------------------------------------------------------------
29.01.2016 News transmitted by EQS Schweiz AG. www.eqs.com - news archive:
http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.
--------------------------------------------------------------------------------

Language: English

Company:  LifeWatch AG

          Baarerstrasse 139

          6300  Zug

          Switzerland

Phone:    +41 41 728 67 78

Internet: www.lifewatch.com

ISIN:     CH0012815459

Valor:    811189

Listed:   Regulated Unofficial Market in Berlin, Stuttgart; Open Market in
Frankfurt ; SIX


End of News EQS Group News Service
--------------------------------------------------------------------------------
433293  29.01.2016 
 

 


Weitere Meldungen: LifeWatch AG

Das könnte Sie auch interessieren: